| Issue |
Natl Sci Open
Volume 1, Number 1, 2022
Special Topic: COVID-19: Virus, Immunity and Vaccines
|
|
|---|---|---|
| Article Number | 20220007 | |
| Number of page(s) | 5 | |
| Section | Life Sciences and Medicine | |
| DOI | https://doi.org/10.1360/nso/20220007 | |
| Published online | 24 March 2022 | |
- Wang C, Horby PW, Hayden FG et al. A novel coronavirus outbreak of global health concern. Lancet 2020; 395 : 470-473. [Article] [CrossRef] [PubMed] [Google Scholar]
- Zhu N, Zhang D, Wang W et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382 : 727-733. [Article] [CrossRef] [PubMed] [Google Scholar]
- Johns Hopkins University. Coronavirus Resource Center. https://www.arcgis.com/apps/dashboards/bda7594740fd40299423467b48e9ecf6. 2021. [Google Scholar]
- World Health Organisation. COVID-19 vaccine tracker and landscape. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. 2021. [Google Scholar]
- Ritchie H, Mathieu E, Rodés-Guirao L, et al. Coronavirus pandemic (COVID-19). Published online at OurWorldInData.org. https://ourworldindata.org/coronavirus. 2020. [Google Scholar]
- Bok K, Sitar S, Graham BS et al. Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. Immunity 2021; 54 : 1636-1651. [Article] [CrossRef] [PubMed] [Google Scholar]
- Shimabukuro TT, Cole M, Su JR Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US—December 14, 2020–January 18, 2021. JAMA 2021; 325 : 1101. [Article] [CrossRef] [PubMed] [Google Scholar]
- Tregoning JS, Flight KE, Higham SL et al. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol 2021; 21 : 626-636. [Article] [CrossRef] [PubMed] [Google Scholar]
- European Medicines Agency. DHPC: COVID-19 vaccine AstraZeneca: risk of thrombocytopenia and coagulation disorders. https://www.ema.europa.eu/en/medicines/dhpc/vaxzevria-previously-covid-19-vaccineastrazeneca-risk-thrombocytopenia-coagulationdisorders. 2021. [Google Scholar]
- Food and Drug Administration. Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine. https://www.fda.gov/news-events/press-announcements/joint-cdc-and-fda-statement-johnson-johnson-covid-19-vaccine. 2021. [Google Scholar]
- Lee EJ, Cines DB, Gernsheimer T et al. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol 2021; 96 : 534-537. [Article] [CrossRef] [PubMed] [Google Scholar]
- Shay DK, Gee J, Su JR, et al. Safety monitoring of the Janssen (Johnson & Johnson) COVID-19 vaccine—United States, March–April 2021. 2021, : 680–684. [Google Scholar]
- Scully M, Singh D, Lown R et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021; 384 : 2202-2211. [Article] [CrossRef] [PubMed] [Google Scholar]
- Shaw RH, Stuart A, Greenland M et al. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet 2021; 397 : 2043-2046. [Article] [CrossRef] [PubMed] [Google Scholar]
- World Health Organization. Tracking SARS-CoV-2 variants. https://www.who.int/en/activities/trackingSARS-CoV-2-variants/. 2021. [Google Scholar]
- Zhou HY, Ji CY, Fan H et al. Convergent evolution of SARS-CoV-2 in human and animals. Protein Cell 2021; 12 : 832-835. [Article] [CrossRef] [PubMed] [Google Scholar]
- Parry H, Bruton R, Stephens C et al. Extended interval BNT162b2 vaccination enhances peak antibody generation. NPJ Vaccines 2022; 7 : 14. [Article] [CrossRef] [PubMed] [Google Scholar]
- Boekel L, Kummer LY, van Dam KPJ et al. Adverse events after first COVID-19 vaccination in patients with autoimmune diseases. Lancet Rheumatol 2021; 3 : e542-e545. [Article] [CrossRef] [PubMed] [Google Scholar]
- Connolly CM, Ruddy JA, Boyarsky BJ et al. Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis 2021; 80 : 1100-1101. [Article] [CrossRef] [PubMed] [Google Scholar]
- Damiani G, Allocco F, Malagoli P COVID‐19 vaccination and patients with psoriasis under biologics: real‐life evidence on safety and effectiveness from Italian vaccinated healthcare workers. Clin Exp Dermatol 2021; 46 : 1106-1108. [Article] [CrossRef] [PubMed] [Google Scholar]
- Watad A, De Marco G, Mahajna H et al. Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA/DNA SARS-CoV-2 vaccination. Vaccines 2021; 9 : 435. [Article] [CrossRef] [PubMed] [Google Scholar]
- Wack S, Patton T, Ferris LK COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: review of available evidence. J Am Acad Dermatol 2021; 85 : 1274-1284. [Article] [CrossRef] [PubMed] [Google Scholar]
- Fenrich M, Mrdenovic S, Balog M et al. SARS-CoV-2 dissemination through peripheral nerves explains multiple organ injury. Front Cell Neurosci 2020; 14 : 229. [Article] [CrossRef] [PubMed] [Google Scholar]
- Cañete PF, Vinuesa CG COVID-19 makes B cells forget, but T cells remember. Cell 2020; 183 : 13-15. [Article] [CrossRef] [PubMed] [Google Scholar]
- Zhang, J, Lin, H, Ye, B, et al. One-year sustained cellular and humoral immunities of COVID-19 convalescents. 2021;. [Google Scholar]
- Bertoletti A, Le Bert N, Qui M et al. SARS-CoV-2-specific T cells in infection and vaccination. Cell Mol Immunol 2021; 18 : 2307-2312. [Article] [CrossRef] [PubMed] [Google Scholar]
- Reynolds CJ, Pade C, Gibbons JM et al. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science 2021; 372 : 1418-1423. [Article] [NASA ADS] [CrossRef] [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.